Two years later, Novo Nordisk’s $3.3 billion buyout of Dicerna Pharmaceuticals’ RNAi platform is beginning to pay off.
Novo scored an approval on Monday for nedosiran, an RNAi therapy developed by Dicerna to treat a rare kidney disease called primary hyperoxaluria type 1 (PH1). The drug, marketed as Rivfloza, is…
Click here to view original post
